|
| | HB4556 Enrolled | | LRB102 23790 CPF 33826 b |
|
|
1 | | AN ACT concerning health.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Overdose Prevention and Harm Reduction Act |
5 | | is amended by changing Section 5 and by adding Section 10 as |
6 | | follows: |
7 | | (410 ILCS 710/5)
|
8 | | Sec. 5. Needle and hypodermic syringe access program. |
9 | | (a) Any governmental or nongovernmental organization, |
10 | | including a local health department, community-based |
11 | | organization, or a person or entity, that promotes |
12 | | scientifically proven ways of mitigating health risks |
13 | | associated with drug use and other high-risk behaviors may |
14 | | establish and operate a needle and hypodermic syringe access |
15 | | program. The objective of the program shall be accomplishing |
16 | | all of the following: |
17 | | (1) reducing the spread of HIV, AIDS, viral hepatitis, |
18 | | and other bloodborne diseases; |
19 | | (2) reducing the potential for needle stick injuries |
20 | | from discarded contaminated equipment; and |
21 | | (3) facilitating connections or linkages to |
22 | | evidence-based treatment.
|
23 | | (b) Programs established under this Act shall provide all |
|
| | HB4556 Enrolled | - 2 - | LRB102 23790 CPF 33826 b |
|
|
1 | | of the following: |
2 | | (1) Disposal of used needles and hypodermic syringes. |
3 | | (2) Needles, hypodermic syringes, and other safer drug |
4 | | consumption supplies, at no cost and in quantities |
5 | | sufficient to ensure that needles, hypodermic syringes, or |
6 | | other supplies are not shared or reused. |
7 | | (3) Educational materials or training on: |
8 | | (A) overdose prevention and intervention; and |
9 | | (B) the prevention of HIV, AIDS, viral hepatitis, |
10 | | and other common bloodborne diseases resulting from |
11 | | shared drug consumption equipment and supplies. |
12 | | (4) Access to opioid antagonists approved for the |
13 | | reversal of an opioid overdose, or referrals to programs |
14 | | that provide access to opioid antagonists approved for the |
15 | | reversal of an opioid overdose.
|
16 | | (5) Linkages to needed services, including mental |
17 | | health treatment, housing programs, substance use disorder |
18 | | treatment, and other relevant community services. |
19 | | (6) Individual consultations from a trained employee |
20 | | tailored to individual needs. |
21 | | (7) If feasible, a hygienic, separate space for |
22 | | individuals who need to administer a prescribed injectable |
23 | | medication that can also be used as a quiet space to gather |
24 | | composure in the event of an adverse on-site incident, |
25 | | such as a nonfatal overdose. |
26 | | (8) If feasible, access to on-site drug adulterant |
|
| | HB4556 Enrolled | - 3 - | LRB102 23790 CPF 33826 b |
|
|
1 | | testing supplies such as reagents, test strips, or |
2 | | quantification instruments that provide critical real-time |
3 | | information on the composition of substances obtained for |
4 | | consumption . |
5 | | (c) Notwithstanding any provision of the Illinois |
6 | | Controlled Substances Act, the Drug Paraphernalia Control Act, |
7 | | or any other law, no employee or volunteer of or participant in |
8 | | a program established under this Act shall be charged with or |
9 | | prosecuted for possession of any of the following: |
10 | | (1) Needles, hypodermic syringes, or other drug |
11 | | consumption paraphernalia obtained from or returned, |
12 | | directly or indirectly, to a program established under |
13 | | this Act. |
14 | | (2) Residual amounts of a controlled substance |
15 | | contained in used needles, used hypodermic syringes, or |
16 | | other used drug consumption paraphernalia obtained from or |
17 | | returned, directly or indirectly, to a program established |
18 | | under this Act. |
19 | | (3) Drug adulterant testing supplies such as reagents, |
20 | | test strips, or quantification instruments obtained from |
21 | | or returned, directly or indirectly, to a program |
22 | | established under this Act or a pharmacy, hospital, |
23 | | clinic, or other health care facility or medical office |
24 | | dispensing drug adulterant testing supplies in accordance |
25 | | with Section 10. This paragraph also applies to any |
26 | | employee or customer of a pharmacy, hospital, clinic, or |
|
| | HB4556 Enrolled | - 4 - | LRB102 23790 CPF 33826 b |
|
|
1 | | other health care facility or medical office dispensing |
2 | | drug adulterant testing supplies in accordance with |
3 | | Section 10 . |
4 | | (4) Any residual amounts of controlled substances used |
5 | | in the course of testing the controlled substance to |
6 | | determine the chemical composition and potential threat of |
7 | | the substances obtained for consumption that are obtained |
8 | | from or returned, directly or indirectly, to a program |
9 | | established under this Act.
This paragraph also applies to |
10 | | any person using drug adulterant testing supplies procured |
11 | | in accordance with Section 10 of this Act. |
12 | | In addition to any other applicable immunity or limitation |
13 | | on civil liability, a law enforcement officer who, acting on |
14 | | good faith, arrests or charges a person who is thereafter |
15 | | determined to be entitled to immunity from prosecution under |
16 | | this subsection (c) shall not be subject to civil liability |
17 | | for the arrest or filing of charges. |
18 | | (d) Prior to the commencing of operations of a program |
19 | | established under this Act, the governmental or |
20 | | nongovernmental organization shall submit to the Illinois |
21 | | Department of Public Health all of the following information: |
22 | | (1) the name of the organization, agency, group, |
23 | | person, or entity operating the program; |
24 | | (2) the areas and populations to be served by the |
25 | | program; and |
26 | | (3) the methods by which the program will meet the |
|
| | HB4556 Enrolled | - 5 - | LRB102 23790 CPF 33826 b |
|
|
1 | | requirements of subsection (b) of this Section. |
2 | | The Department of Public Health may adopt rules to |
3 | | implement this subsection.
|
4 | | (Source: P.A. 101-356, eff. 8-9-19.) |
5 | | (410 ILCS 710/10 new) |
6 | | Sec. 10. Dispensing of drug adulterant testing supplies. A |
7 | | pharmacist, physician, advanced practice registered nurse, or |
8 | | physician assistant, or the pharmacist's, physician's, |
9 | | advanced practice registered nurse's, or physician assistant's |
10 | | designee, may dispense drug adulterant testing supplies to any |
11 | | person. Any drug adulterant testing supplies dispensed under |
12 | | this Section must be stored at a licensed pharmacy, hospital, |
13 | | clinic, or other health care facility or at the medical office |
14 | | of a physician, advanced practice registered nurse, or |
15 | | physician assistant and in a manner that limits access to the |
16 | | drug adulterant testing supplies to pharmacists, physicians, |
17 | | advanced practice registered nurses, or physician assistants |
18 | | employed at the pharmacy, hospital, clinic, or other health |
19 | | care facility or medical office and any persons designated by |
20 | | the pharmacist, physician, advanced practice registered nurse, |
21 | | or physician assistant. Drug adulterant testing supplies |
22 | | dispensed at a retail store containing a pharmacy under this |
23 | | Section may be dispensed only from the pharmacy department of |
24 | | the retail store. No quantity of drug adulterant testing |
25 | | supplies greater than necessary to conduct 5 assays of |